STAP1 Genotype

You are reading about a genetic test whose original clinical premise has not held up. STAP1 (signal transducing adaptor family member 1) was originally proposed as a possible fourth gene behind familial hypercholesterolemia, the inherited condition that drives lifelong high LDL cholesterol and early heart disease. Larger studies, including knockout mouse experiments and reanalysis by the original discovery group, have since concluded that STAP1 is unlikely to cause familial hypercholesterolemia. The result you get from this test today is best treated as a historical genetic finding rather than a meaningful predictor of your cholesterol or heart risk.

That makes this test most useful in one situation: when you have a strong personal or family history of very high cholesterol or early heart disease, your standard FH gene panel (LDLR, APOB, PCSK9) came back negative, and you want a complete record of genes that have historically been investigated. Going in with realistic expectations matters more here than with most tests, because the weight of current evidence suggests a STAP1 variant on its own does not change your cholesterol or your risk.

What STAP1 Actually Is

STAP1 is a gene that codes for a small messenger protein inside immune cells, helping pass signals between other proteins involved in immune cell activity, including T cells, B cells, and natural killer T cells. It is not an enzyme that breaks down cholesterol, and it is not a cholesterol receptor like LDLR. Why an immune-cell signaling protein would influence cholesterol levels was never mechanistically clear, which is part of why scientists have not been able to confirm a role.

The test itself reads the DNA sequence of the STAP1 gene from a sample of your cells and reports whether you carry any rare variants. The result is a one-time genetic readout. The spelling of your STAP1 gene was set at conception and will not change over your lifetime.

The Original Familial Hypercholesterolemia Link

The case for STAP1 began with a 2014 study of families with autosomal dominant hypercholesterolemia, where researchers reported rare STAP1 variants such as p.Glu97Asp in carriers who had higher total and LDL cholesterol than their non-carrier relatives. That finding pushed STAP1 onto many of the expanded genetic panels used today to investigate inherited cholesterol problems.

This is why, even now, you will often see STAP1 listed alongside the established FH genes LDLR (LDL receptor), APOB (apolipoprotein B), and PCSK9 (proprotein convertase subtilisin/kexin type 9) on commercial sequencing panels. The inclusion reflects historical evidence, not current consensus.

Why the Evidence Turned Against STAP1

In a Spanish study of 400 people with clinically diagnosed familial hypercholesterolemia, researchers found 17 rare STAP1 variants and tested whether they tracked with high cholesterol within families. They did not. Across seven families, carriers of predicted-pathogenic variants sometimes had LOWER LDL cholesterol than their non-carrier relatives, the opposite of what you would expect if STAP1 were causing the disease.

A German study compared carriers of rare STAP1 variants with non-carriers from a general population. There were no statistically significant differences in lipid measurements between the two groups. The authors concluded they could not call STAP1 a causative FH gene based on these data.

A separate case report described a man with a rare STAP1 missense variant where the variant did not cosegregate cleanly within his family: it appeared in some relatives with high cholesterol but did not consistently travel with the disease across generations. This kind of failure of cosegregation, where the gene change and the disease do not travel together through a family, is a strong signal that the variant is not the cause.

The most decisive evidence came from the original discovery group itself. In a 2020 study combining knockout mouse experiments, human carrier reanalysis, coculture assays, and UK Biobank data, the researchers concluded directly that STAP1 is not a familial hypercholesterolemia gene. A second independent knockout mouse study published the same year reached the same conclusion: mice without STAP1 had normal plasma cholesterol.

Making Sense of the Findings

On the surface, this can look like a contradiction: the original study found a link, the follow-ups did not. The current consensus, reinforced by mouse genetics, human population data, and reassessment by the original discovery group, is that STAP1 is unlikely to be a true FH gene. The original carriers may have had high cholesterol because of other genetic or lifestyle reasons, with the STAP1 variant traveling along for the ride. Your result should be interpreted in that light: a rare variant in STAP1 is not a diagnosis and, based on current evidence, likely does not meaningfully shape your cardiovascular risk.

What This Means for Your Heart Risk

Multiple lines of evidence, human cosegregation studies, knockout mouse models, and population-level data, all point in the same direction: a STAP1 variant does not reliably predict high cholesterol or elevated heart attack risk beyond what your standard labs and family history already suggest.

That is why the real cardiovascular workup still rests on your LDL cholesterol, ApoB (apolipoprotein B, the count of cholesterol-carrying particles in your blood), Lipoprotein(a), and your family history. A STAP1 finding adds historical context, not a verdict.

A Separate Line of Research in Liver Disease

In a different context, researchers have studied STAP1 in chronic hepatitis B infection by measuring DNA methylation, a chemical tag on DNA that turns genes up or down without changing the spelling itself. In immune cells from people with HBV-related liver disease, STAP1 methylation rises as liver damage progresses, and higher methylation has been linked to worse survival in liver cancer. The genetic test described here does NOT measure methylation. It reads the spelling of the gene. So this line of evidence, while real, does not apply to your result.

Your One-Time Result

Because your STAP1 genotype is fixed at birth, this is a once-in-a-lifetime test. There is no retesting cadence, no follow-up panel of the same gene to track. The value comes from feeding the result into decisions you make over years.

What does need ongoing tracking is your cholesterol picture. Whether or not you carry a STAP1 variant, your LDL cholesterol, ApoB, Lp(a), and other lipid markers should be monitored at least annually, and every 3 to 6 months while you are actively changing diet, exercise, or medications. This monitoring cadence is general lipid-management practice, not specific to STAP1. The genetic result is a backdrop. Your phenotype, what is actually happening in your blood, is what you act on.

What to Do If a Rare Variant Is Found

If your report shows a rare STAP1 variant, especially one labeled as predicted-pathogenic or a variant of uncertain significance, the next step is not to assume you have familial hypercholesterolemia. Given that current evidence argues against STAP1 as an FH gene, the more important task is to gather a complete cardiovascular picture and look at genes with stronger validity.

• Confirm your lipid phenotype: order a full lipid panel with ApoB and Lp(a) if you have not already. The number that matters for action is your cholesterol particle burden, not the gene result alone.
• Review the rest of the FH panel: if STAP1 was the only gene tested, consider sequencing LDLR, APOB, and PCSK9, which carry far stronger evidence as FH causes.
• Map your family: ask first-degree relatives (parents, siblings, children) about their cholesterol numbers and any history of heart attack or stroke under age 55 in men or 65 in women.
• Consider a genetic counselor: a counselor can help you interpret a variant of uncertain significance, explain why STAP1's link to FH is now widely questioned, and decide whether cascade testing in relatives makes sense.

When Results Can Be Misleading

Genetic tests have their own set of pitfalls that differ from blood-based markers. With STAP1 specifically, a few stand out.

• Variant panel coverage: the assay only detects the specific variants it is designed to read. A negative result does not rule out every possible change in STAP1, only the ones the test looks for.
• Variants of uncertain significance: because STAP1's clinical meaning has been called into question, you may receive a result flagged as uncertain. This means the lab found a rare change but cannot say whether it matters, and current evidence suggests most STAP1 variants do not affect cholesterol.
• Ethnic-specific differences: the studies questioning STAP1's role were done largely in European cohorts. How rare STAP1 variants behave across other ancestral backgrounds is less well studied.
• Clinical-grade versus direct-to-consumer reports: if you have seen a STAP1 mention on a 23andMe or similar report, the variant coverage and interpretation standards differ from a clinical sequencing panel. A clinical-grade test is the appropriate basis for any medical decision.

What a Positive Result Doesn't Guarantee

Even for well-established FH genes, carrying a risk variant does not guarantee disease will develop. The likelihood that a gene change actually produces the expected condition is called penetrance. For STAP1, the broader question is no longer just about penetrance: knockout mice and population data suggest the gene may not meaningfully influence cholesterol at all. A rare variant in your STAP1 gene is best treated as a historical finding from a gene that did not pan out, not a diagnosis you carry.